CD274 and cancer: A systematic comprehensive description identified that PD‐1 and PD‐L1 blocking immunotherapy in cancer patients increased the risk of TB reactivation, with an estimated TB incidence rate 35 times higher than that in the general population and a high mortality rate of approximately 22.2% [84].